Placing to raise £2 million

RNS Number : 0543I

N4 Pharma PLC

09 December 2020

 

9 December 2020

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 ("MAR").  In addition, market soundings (as defined in MAR) were taken in respect of the Placing with the result that certain persons became aware of inside information (as defined in MAR), as permitted by MAR.  This inside information is set out in this announcement.  Therefore, those persons that received inside information in a market sounding are no longer in possession of such inside information relating to the Company and its securities.

N4 Pharma plc

("N4 Pharma" or the "Company")

Placing to raise £2 million

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that it has raised £2 million (before expenses) through a placing of 25,000,000 new ordinary shares of 0.4p each in the Company (the "Placing Shares") at an issue price of 8p per Placing Share (the "Placing").  The Placing, which was significantly oversubscribed, was undertaken by SP Angel Corporate Finance LLP.

The net proceeds of the Placing will be used for:

· the extension of the formulation and current stability work covering DNA and mRNA formulations;

· research on and evaluation of an additional asset to add to the Company portfolio;

· business development driven by study results pending over next six months; and

· ongoing working capital.

Nigel Theobald, Chief Executive of N4 Pharma, commented: "We are delighted with the positive response to our recent formulation work.  With vaccines and their delivery very much in the public consciousness we continue to grow our data package to present Nuvec® as a viable delivery technology solution to improve the delivery, storage and transportation of multiple existing and new vaccines.

"Whilst we are well funded for all existing work streams these additional funds will enable us to plan for follow on studies and more product focussed experiments as we move towards collaborations."  

Application for Admission

The Placing has been conducted utilising the Company's existing share authorities.  Application has been made for the Placing Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place and that trading will commence on AIM at 8.00 a.m. on or around 14 December 2020.  Once issued, the new Ordinary Shares will rank pari passu with the Company's existing ordinary shares. 

Total Voting Rights

Following Admission, the enlarged issued share capital of the Company will comprise 181,080,349 Ordinary Shares of 0.4 pence each.  The Company does not hold any ordinary shares in treasury.  Consequently, 181,080,349 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Enquiries:

N4 Pharma plc
Nigel Theobald, CEO	Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP	Tel: [phone]
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited	Tel: [phone]
Joint Broker
Andy Thacker
IFC Advisory Ltd	Tel: [phone]
Financial PR
Graham Herring
Zach Cohen

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity.  As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

END

 

 

IOETLBPTMTMMMPM